STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Initial Public Offering	Public Offering	Convertible Preferred Stock	Common Stock	Common Stock Initial Public Offering	Common Stock Public Offering	Additional Paid-in Capital	Additional Paid-in Capital Initial Public Offering	Additional Paid-in Capital Public Offering	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance at Dec. 31, 2018				$ 107,266
Beginning Balance (in shares) at Dec. 31, 2018				13,789,770
Beginning Balance at Dec. 31, 2018	$ (64,426)							$ 1,381			$ (65,807)
Beginning Balance (in shares) at Dec. 31, 2018					1,802,134
Issuance of Series C and D preferred stock, net of issuance costs of $135				$ 70,792
Issuance of Series C and D preferred stock, net of issuance costs of $135 (in shares)				5,488,836
Exercise of common stock options	131							131
Exercise of common stock options (in shares)					182,088
Stock-based compensation expense	1,094							1,094
Net loss	$ (26,883)										(26,883)
Ending Balance at Dec. 31, 2019				$ 178,058
Ending Balance (in shares) at Dec. 31, 2019	19,278,606			19,278,606
Ending Balance at Dec. 31, 2019	$ (90,084)							2,606			(92,690)
Ending Balance (in shares) at Dec. 31, 2019					1,984,222
Offering of common stock		$ 138,000	$ 133,308			$ 1	$ 1		$ 137,999	$ 133,307
Offering of common stock (in shares)						8,625,000	5,796,000
Issuance costs associated with offering of common stock		$ (12,790)	$ (8,546)						$ 12,790	$ 8,546
Conversion to Common Stock (in shares)				19,278,606
Conversion to Common Stock	178,058			$ (178,058)	$ 2			178,056
Conversion to Common Stock (in shares)					19,278,606
Issuance of common stock related to acquired-in- process research and development	19,843							19,843
Issuance of common stock related to acquired-in-process research and development (in shares)					871,494
Exercise of common stock options	443							443
Exercise of common stock options (in shares)					117,093
Stock-based compensation expense	5,278							5,278
Unrealized loss on available-for-sale securities	(31)											$ (31)
Net loss	(73,703)										(73,703)
Ending Balance at Dec. 31, 2020	$ 289,776				$ 4			456,196			(166,393)	(31)
Ending Balance (in shares) at Dec. 31, 2020	36,672,415				36,672,415
Offering of common stock	$ 50,000							50,000
Offering of common stock (in shares)					2,597,402
Issuance costs associated with offering of common stock	(1,852)							(1,852)
Exercise of common stock options	$ 986							986
Exercise of common stock options (in shares)	160,303				160,303
Stock-based compensation expense	$ 12,853							12,853
Unrealized loss on available-for-sale securities	(72)											(72)
Net loss	(78,715)										(78,715)
Ending Balance at Dec. 31, 2021	$ 272,976				$ 4			$ 518,183			$ (245,108)	$ (103)
Ending Balance (in shares) at Dec. 31, 2021	39,430,120				39,430,120